Exjade, known chemically as Deferasirox, is a chelating agent primarily used for the treatment of chronic iron overload due to blood transfusions in patients with conditions such as thalassemia and sickle cell disease. The substance forms stable complexes with ferric ions (Fe3+), facilitating their excretion from the body, primarily through the feces. Exjade is characterized by its ability to selectively bind iron, reducing the risk of iron-induced organ damage. It is typically administered orally and is known for its relatively favorable safety profile compared to other iron chelators. The compound is a white to off-white powder, soluble in water, and has a specific molecular structure that allows it to effectively coordinate with iron ions. Its pharmacokinetics involve absorption in the gastrointestinal tract, with peak plasma concentrations occurring within a few hours post-administration. Monitoring of renal and hepatic function is essential during treatment, as Exjade can have side effects, including gastrointestinal disturbances and potential renal toxicity. Overall, Exjade plays a crucial role in managing iron overload in affected patients.

Exjade Fe3+ chelate

554435-83-5: Exjade, known chemically as Deferasirox, is a chelating agent primarily used for the treatment of chronic iron overload due to blood transfusions in patients with conditions such as thalassemia and sickle cell disease. The substance forms stable complexes with ferric ions (Fe3+), facilitating their excretion from the body, primarily through the feces. Exjade is characterized by its ability to selectively bind iron, reducing the risk of iron-induced organ damage. It is typically administered orally and is known for its relatively favorable safety profile compared to other iron chelators. The compound is a white to off-white powder, soluble in water, and has a specific molecular structure that allows it to effectively coordinate with iron ions. Its pharmacokinetics involve absorption in the gastrointestinal tract, with peak plasma concentrations occurring within a few hours post-administration. Monitoring of renal and hepatic function is essential during treatment, as Exjade can have side effects, including gastrointestinal disturbances and potential renal toxicity. Overall, Exjade plays a crucial role in managing iron overload in affected patients.

<p>Deferasirox (Fe3+ chelate) is an iron chelator with anticancer activity and can be used to study iron overload.</p>

CAS 554435-83-5

Exjade Fe3+ chelate

Deferasirox (Fe3+ chelate)

Ref: TM-T13639

Deferasirox Fe3+ Chelate

Ref: 3D-FD64999